XOMA (GBIO) bid keeps $4.2913 plus CVR, moves tender expiry to Feb 6

Rhea-AI Filing Summary

XOMA Royalty Corporation, through its subsidiary XRA 7 Corp., is conducting a tender offer to acquire all outstanding shares of Generation Bio Co. (GBIO) common stock. Each share is being offered $4.2913 in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (CVR) that may provide additional cash payments under a CVR agreement.

This amendment updates only the timing of the offer. The expiration has been changed from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026. All other terms and conditions of the tender offer remain the same as previously described in the offer materials.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

(Amendment No. 1)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

GENERATION BIO CO.

(Name of Subject Company (Issuer))

XRA 7 CORP.

(Name of Filing Persons (Co-Offeror))

XOMA ROYALTY CORPORATION

(Name of Filing Persons (Co-Offeror))

Common Stock, Par Value $0.0001 Per Share

(Title of Class of Securities)

37148K209

(CUSIP Number of Class of Securities)

Owen Hughes

XOMA Royalty Corporation

2200 Powell Street, Suite 310

Emeryville, California 94608

Tel. (510) 204-7200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

Copies to:

Ryan A. Murr

Branden C. Berns

Gibson, Dunn & Crutcher LLP

One Embarcadero Center, Suite 2600

San Francisco, CA 94111

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐  Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐  Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

AMENDMENT NO. 1

TO

TENDER OFFER

This Amendment No. 1 to Tender Offer Statement on Schedule TO (this “Amendment”) relates to the offer (the “Offer”) by XOMA Royalty Corporation, a Nevada corporation (“Parent”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, “Buyer Entities”), to acquire all of the issued and outstanding shares (the “Company Shares”) of common stock, par value $0.0001 per share (the “Company Common Stock”), of Generation Bio Co., a Delaware corporation (the “Company”), for (i) $4.2913 per Company Share, payable in cash, without interest and less any applicable tax withholding (such amount, or any different amount per share paid pursuant to the Offer, the “Cash Amount”), plus (ii) one non-tradable contingent value right per Company Share (each, a “CVR”), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of the CVR Agreement (as defined in the Offer to Purchase) (the Cash Amount plus one CVR, together, the “Offer Price”), all upon the terms and subject to the conditions described in the Offer to Purchase, dated January 9, 2026 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal, copies of which were included as exhibits to the original Schedule TO-T filed in connection with the Offer.

This Amendment is being filed to amend the date on which the Offer will expire from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026 (the “Expiration Date”). This Amendment does not amend or modify any other terms of the Offer set forth in the Offer to Purchase or in the other Offer materials originally mailed to the Company’s stockholders, except for the Expiration Date.

The information in the Offer to Purchase, including all schedules and annexes thereto, is hereby expressly incorporated herein by reference in response to all the items of this Amendment.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 12, 2026

XRA 7 Corp.
By:		/s/ Owen Hughes
		Name: Owen Hughes
		Title: President, Treasurer and Secretary
XOMA Royalty Corporation
By:		/s/ Owen Hughes
		Name: Owen Hughes
		Title: Chief Executive Officer

FAQ

What is XOMA offering for each Generation Bio (GBIO) share in this tender offer?

Each Generation Bio share is being offered $4.2913 in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (CVR) that can provide additional cash payments based on the terms of the CVR agreement.

Has the expiration date of the Generation Bio (GBIO) tender offer changed?

Yes. The expiration date has been changed to one minute after 11:59 p.m. Eastern Time on February 6, 2026, instead of one minute after 11:59 p.m. Eastern Time on February 8, 2026.

Did the amendment change any economic terms of the Generation Bio tender offer price?

No. The amendment states that only the Expiration Date was changed. The consideration remains $4.2913 in cash plus one non-tradable CVR per share, under the same terms described in the offer to purchase and related materials.

Who is making the tender offer for Generation Bio (GBIO) shares?

The offer is being made by XOMA Royalty Corporation (the parent) and its wholly owned subsidiary XRA 7 Corp., which together are referred to as the buyer entities.

What type of security is subject to this Generation Bio tender offer?

The offer covers all issued and outstanding shares of Generation Bio Co. common stock, with a par value of $0.0001 per share.

What is the role of the contingent value right (CVR) in the Generation Bio offer?

For each Generation Bio share tendered, holders receive one non-tradable CVR, which represents the right to receive certain additional cash payments if conditions described in the CVR agreement are met.